Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04892914 · ClinicalTrials.gov registry record · NA

Embr Thermal Device for Hot Flash Management in Prostate Cancer

A NA study of Prostate Cancer and Hot Flashes, sponsored by Embr Labs.

Completed
Registry status
NA
Development phase
57
Enrollment target
1
Study location

NCT04892914: Completed NA study of Prostate Cancer and Hot Flashes, sponsored by Embr Labs.

NCT04892914 is a NA study of Prostate Cancer and Hot Flashes that has completed, run by Embr Labs. The registered enrollment target is 57 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04892914, a NA study of Prostate Cancer and Hot Flashes, has completed, sponsored by Embr Labs.

COMPLETED
Registry status
NA
Development phase
57 participants
Enrollment target
1
Study location

Study Summary

This study is being conducted to evaluate if the Embr thermal device is useful for men who experience bothersome hot flashes as a result of prostate cancer treatment.

Primary Outcome

Number of minutes logged with the Embr device.

Interventions

  • DEVICE Embr thermal device

Study Locations (1)

Massachusetts

  • Embr Labs (Remote study site) - Boston

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2021-05-28
Est. Completion 2021-12-05
Phase NA
Embr Labs

1 total trials

What the finished NCT04892914 record still lists

NCT04892914 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (91% lower).

The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Embr thermal device is the first listed.

NCT04892914 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04892914 about?

NCT04892914 is a clinical study titled "Embr Thermal Device for Hot Flash Management in Prostate Cancer". This study is being conducted to evaluate if the Embr thermal device is useful for men who experience bothersome hot flashes as a result of prostate cancer treatment.

What is the current status of trial NCT04892914?

This trial is currently completed. It is a NA study. The enrollment target is 57 participants. The study started on 2021-05-28. Estimated completion is 2021-12-05.

What conditions does trial NCT04892914 study?

This clinical trial studies the following conditions: Prostate Cancer, Hot Flashes.

What interventions are being tested in trial NCT04892914?

The interventions under investigation include: Embr thermal device (DEVICE).

Who is sponsoring clinical trial NCT04892914?

This trial is sponsored by Embr Labs, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04892914 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04892914's enrollment target sits among peer trials

57 452nd of 735 higher than 283 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03521830 · 57 participants · Phase 2

    Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

  • NCT03587701 · 57 participants · Phase 2

    Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

  • NCT04104126 · 57 participants · NA

    Blood Flow Restriction Therapy in Achilles Injury

  • NCT04703842 · 57 participants · Phase 1

    Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04892914, the US trial registry maintained by the National Library of Medicine. NCT04892914 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.